Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -0.3x - -0.3x | -0.3x |
| Selected Fwd EBIT Multiple | -0.3x - -0.3x | -0.3x |
| Fair Value | $0.35 - $0.37 | $0.36 |
| Upside | 40.2% - 49.1% | 44.6% |
| Benchmarks | Ticker | Full Ticker |
| Onconetix, Inc. | ONCO | NasdaqCM:ONCO |
| Arcturus Therapeutics Holdings Inc. | ARCT | NasdaqGM:ARCT |
| iTeos Therapeutics, Inc. | ITOS | NasdaqGM:ITOS |
| Applied Therapeutics, Inc. | APLT | NasdaqGM:APLT |
| Taysha Gene Therapies, Inc. | TSHA | NasdaqGS:TSHA |
| X4 Pharmaceuticals, Inc. | XFOR | NasdaqCM:XFOR |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| ONCO | ARCT | ITOS | APLT | TSHA | XFOR | ||
| NasdaqCM:ONCO | NasdaqGM:ARCT | NasdaqGM:ITOS | NasdaqGM:APLT | NasdaqGS:TSHA | NasdaqCM:XFOR | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | -0.2% | -22.3% | -6.3% | -47.7% | -21.4% | -31.5% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -7788.4% | -553.2% | -177.3% | 11445.9% | -1243.4% | -6592.2% | |
| Prior Fiscal Year | NA | -46.9% | -1171.7% | NA | -461.9% | NA | |
| Latest Fiscal Year | -27161.9% | -62.8% | -448.0% | -645.8% | -1039.5% | -5530.0% | |
| Latest Twelve Months | -735.2% | -62.8% | -448.0% | 43530.7% | -1039.5% | -5530.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 9.43x | 0.69x | -7.09x | 173.85x | 38.42x | 7.60x | |
| EV / LTM EBITDA | -1.3x | -1.1x | 1.6x | 0.4x | -3.8x | -0.1x | |
| EV / LTM EBIT | -1.3x | -1.1x | 1.6x | 0.4x | -3.7x | -0.1x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -3.7x | -1.1x | 1.6x | ||||
| Historical EV / LTM EBIT | -1.0x | -0.5x | -0.1x | ||||
| Selected EV / LTM EBIT | -0.3x | -0.3x | -0.3x | ||||
| (x) LTM EBIT | (141) | (141) | (141) | ||||
| (=) Implied Enterprise Value | 41 | 43 | 45 | ||||
| (-) Non-shareholder Claims * | 24 | 24 | 24 | ||||
| (=) Equity Value | 65 | 67 | 69 | ||||
| (/) Shares Outstanding | 173.7 | 173.7 | 173.7 | ||||
| Implied Value Range | 0.37 | 0.39 | 0.40 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 0.37 | 0.39 | 0.40 | 0.25 | |||
| Upside / (Downside) | 49.8% | 54.7% | 59.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | ONCO | ARCT | ITOS | APLT | TSHA | XFOR | |
| Enterprise Value | 18 | 106 | (409) | (37) | 320 | 19 | |
| (+) Cash & Short Term Investments | 0 | 237 | 495 | 99 | 139 | 102 | |
| (+) Investments & Other | 0 | 0 | 160 | 0 | 0 | 0 | |
| (-) Debt | (10) | (29) | (5) | (2) | (64) | (78) | |
| (-) Other Liabilities | (7) | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1 | 314 | 241 | 60 | 396 | 43 | |
| (/) Shares Outstanding | 8.3 | 27.1 | 38.2 | 116.4 | 205.0 | 173.7 | |
| Implied Stock Price | 0.09 | 11.58 | 6.32 | 0.52 | 1.93 | 0.25 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.09 | 11.58 | 6.32 | 0.52 | 1.93 | 0.25 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |